Humacyte, Inc.
HUMA
$3.13
$0.123.99%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | 75.90% | 51.88% | 23.07% | 34.92% | -97.92% |
Gross Profit | -75.90% | -51.88% | -23.07% | -34.92% | 97.91% |
SG&A Expenses | 20.38% | 86.32% | 1.53% | 2.90% | -1.91% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 22.79% | 24.87% | 18.06% | 25.94% | 4.66% |
Operating Income | -22.79% | -24.87% | -18.06% | -25.94% | -4.80% |
Income Before Tax | -50.81% | -149.55% | 13.72% | -574.89% | -2.82% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -50.81% | -149.55% | 13.72% | -574.89% | -2.82% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -50.81% | -149.55% | 13.72% | -574.89% | -2.82% |
EBIT | -22.79% | -24.87% | -18.06% | -25.94% | -4.80% |
EBITDA | -24.70% | -28.09% | -21.27% | -30.38% | -6.21% |
EPS Basic | -30.64% | -116.43% | 17.68% | -571.19% | -2.40% |
Normalized Basic EPS | -7.13% | -12.79% | -14.29% | -28.05% | -1.76% |
EPS Diluted | -30.64% | -116.43% | 17.68% | -571.19% | -2.40% |
Normalized Diluted EPS | -7.13% | -12.79% | -14.29% | -28.05% | -1.76% |
Average Basic Shares Outstanding | 15.43% | 15.30% | 4.83% | 0.43% | 0.40% |
Average Diluted Shares Outstanding | 15.43% | 15.30% | 4.83% | 0.43% | 0.40% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |